Given the successes and failures of Merck’s current Keytruda development strategy, a better multi-pronged approach may be needed to optimize current resources.
Posts
Opko Health’s deal with Merck for its experimental Epstein-Barr virus vaccine is potentially worth up to $922.5 million.
Merck released Phase IIb data showing that its hypercholesterolemia hopeful, MK-0616, met the primary endpoint of significantly decreasing low-density lipoprotein cholesterol.
The companies’ are seeking approval of the drug Lynparza in combination with other medications for the treatment of a type of treatment-resistant prostate cancer in adult patients.
The decision comes nearly a month after it scrapped a late-stage study of Keytruda in some prostate cancer patients and puts the drugmaker further behind in its quest to develop a treatment for advanced forms of the most common cancer type in the United States.
The antiviral pill, brand named Lagevrio, could not demonstrate benefits in treatment of COVID patients who do not need oxygen support and are at risk of their disease worsening, the European Medicines Agency said.
“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren wrote to Kathi Vidal, director of the United States Patent and Trademark Office (PTO) in the letter sent on Wednesday
The company announced its experimental personalized mRNA skin cancer vaccine in combination with Merck & Co Inc.’s drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.
The Washington-based biotech is focusing on upcoming label expansions and its promising pipeline.
Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.
